Rize Oncology Inc. (CSE:RIZE)

Canada flag Canada · Delayed Price · Currency is CAD
0.0300
-0.0200 (-40.00%)
Inactive · Last trade price on May 23, 2025
20.00%
Market Cap2.27M
Revenue (ttm)n/a
Net Income (ttm)-792.69K
Shares Out75.74M
EPS (ttm)-0.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume9,548
Average Volume13,246
Open0.0600
Previous Close0.0500
Day's Range0.0300 - 0.0600
52-Week Range0.0150 - 0.1800
Beta2.49
RSI42.27
Earnings DateMay 23, 2025

About Rize Oncology

Rize Oncology Inc. engages in the development of oncology therapeutics. It develops STS-201, a small-molecule drug for the treatment of soft tissue sarcoma. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was founded in 2018 and is based in Kelowna, Canada. [Read more]

Industry Pharmaceutical Preparations
Founded 2018
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol RIZE
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements